| Autor: |
Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, Cocozza M, Cubas-Atienzar AI, Cuevas LE, Cusinato M, Davies BMO, Davis M, Davis P, Duvoix A, Eckersley NM, Forton D, Fraser AJ, Garrod G, Hadcocks L, Hu Q, Johnson M, Kay GA, Klekotko K, Lewis Z, Macallan DC, Mensah-Kane J, Menzies S, Monahan I, Moore CM, Nebe-von-Caron G, Owen SI, Sainter C, Sall AA, Schouten J, Williams CT, Wilkins J, Woolston K, Fitchett JRA, Krishna S, Planche T |
| Jazyk: |
angličtina |
| Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2021 Jan; Vol. 27 (1). Date of Electronic Publication: 2020 Nov 30. |
| DOI: |
10.3201/eid2701.203074 |
| Abstrakt: |
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%-8.5% of persons did not seroconvert 3-6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
